Covidien next to initiate heparin recall
Covidien, formerly Tyco Healthcare, has notified healthcare professionals and the FDA of a voluntary recall of certain lots of Heparin Sodium USP because two lots of the product acquired by the company had a heparin-like contaminant.
To date, Covidien said has not received any adverse event reports related to this issue.
However, the company recommends use of the 32 lots of recalled products manufactured and distributed by Covidien in the U.S. should be discontinued immediately.
Covidien follows two other companies—Baxter International and B. Braun—who have also issued recalls of their heparin products due to contaminants.
Recalling the lots as a precautionary measure, and was initiatially due to a notification received from the supplier, SPL, disclosing that two lots of Heparin Sodium USP Active Pharmaceutical Ingredient acquired by Covidien had a heparin-like contaminant, according to the Mansfield, Mass.-based company.
To date, Covidien said has not received any adverse event reports related to this issue.
However, the company recommends use of the 32 lots of recalled products manufactured and distributed by Covidien in the U.S. should be discontinued immediately.
Covidien follows two other companies—Baxter International and B. Braun—who have also issued recalls of their heparin products due to contaminants.
Recalling the lots as a precautionary measure, and was initiatially due to a notification received from the supplier, SPL, disclosing that two lots of Heparin Sodium USP Active Pharmaceutical Ingredient acquired by Covidien had a heparin-like contaminant, according to the Mansfield, Mass.-based company.